• ACVC Callout
News
ICViewExpert PerspectivesMedical World NewsVideosWebinars
Conference
Infection Control TodaySupplements And Featured Publications
CME/CEJob BoardPartnersSponsoredWhitepapers
Print SubscriptioneNewsletter
Educator of the Year Nomination FormEducator of the Year Official RulesEducator of the Year
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • Expert Perspectives on Personal Protection Guidelines and Standardization Practices
  • Bug of the Month
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
    • News
    • Conference
Advertisement

Researchers Review CDI-Related Mortality

Jun 7, 2012
Article

Clostridium difficile infection (CDI) is a common cause of diarrhea in hospitalized patients. Around the world, the incidence and severity of CDI appears to be increasing, particularly in the northern hemisphere. Mitchell and Gardner (2012) conducted an integrative review to investigate and describe mortality in hospitalized patients with CDI.
 
A search of the literature between Jan. 1, 2005 and April 30, 2011 focusing on mortality and CDI in hospitalized patients was conducted using electronic databases. Papers were reviewed and analyzed individually and themes were combined using integrative methods.

The researchers report that all-cause mortality at 30 days varied from 9 percent to 38 percent. Three studies report attributable mortality at 30 days, varying from 5.7 percent to 6.9 percent. In hospital mortality ranged from 8 percent to 37.2 percent
 
Mitchell and Gardner (2012) concluded that all-cause 30-day mortality appeared to be high, with 15 studies indicating a mortality of 15 percent or greater. Findings support the notion that CDI is a serious infection and measures to prevent and control CDI are needed. Future studies investigating the mortality of CDI in settings outside of Europe and North America are needed. Similarly, future studies should include data on patient co-morbidities. Their research was published in Antimicrobial Resistance and Infection Control.

Reference: Mitchell BG and Gardner A. Mortality and Clostridium difficile infection: a review. Antimicrobial Resistance and Infection Control 2012, 1:20 doi:10.1186/2047-2994-1-20
 

Related Videos
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Photo of a model operating room. (Photo courtesy of Indigo-Clean and Kenall Manufacturing)
GIANTmicrobes at the 2023 APIC Annual Conference and Exhibition.  (Photo by the author)
Related Content

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023
Related Content
Advertisement

An infection preventionist taking off her mask. (Adobe Stock, unknown)

I’m Not Just an Infection Preventionist

September 26th 2023
Article

Infection preventionists (IP) can come from many different backgrounds. This is 1 opinion from 1 very successful IP who doesn't have an RN or a BSN and the bullying that sometimes occurs.


(Adobe Stock FILE #:  56169337 by thinglass)

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023
Article

Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.


Influenza, RSV, and COVID-19 (AdobeStock_249346161, AdobeStock_538653843,AdobeStock_471755796)

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023
Article

The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.


weekly rounds with infection control today

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Article

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.


NIH Announces HIV Vaccine Clinical Trial Begins

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023
Article

A new preventative vaccine has been developed incorporating technology funded by the NIH since 2004. The trials will be conducted in the United States and South Africa.


Vial of COVID-19 vaccine, bottle for injection with syringe.  (Adobe Stock 331786954 by myskin)

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023
Article

Randomized controlled trials show masks are effective. With COVID-19, even one mistake in protective gear usage could lead to infection and obscure results.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News